Sugi Predict

Sugi Predict / Compounds / SCHEMBL162756

SCHEMBL162756

SCHEMBL162756

CN[C@H](CCCNC(=N)N)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 1/20 0.38
▸ ITGB3 P05106 1/20 0.37
▸ ITGA2B P08514 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ C3AR1 Q16581 1/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ NPY4R P50391 8/20 0.35
▸ NPY1R P25929 5/20 0.35
▸ NPY2R P49146 3/20 0.35
▸ NPY5R Q15761 3/20 0.35
▸ CACNA1B Q00975 2/20 0.35
▸ NOD1 Q9Y239 2/20 0.35
▸ OTC P00480 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL93472 1.00 FOLH1 (0.38) FOLH1ITGB3ITGA2BALOX15C3AR1
SCHEMBL17769024 1.00 FOLH1 (0.38) FOLH1ITGB3ITGA2BALOX15C3AR1
SCHEMBL93473 1.00 FOLH1 (0.38) FOLH1ITGB3ITGA2BALOX15C3AR1
Hydrochloric Acid SCHEMBL1578565 0.98 FOLH1 (0.37) FOLH1ITGB3ITGA2BALOX15C3AR1
Hydrochloric Acid SCHEMBL7367067 0.98 FOLH1 (0.37) FOLH1ITGB3ITGA2BALOX15C3AR1
Hydrochloric Acid SCHEMBL974818 0.98 FOLH1 (0.37) FOLH1ITGB3ITGA2BALOX15C3AR1
Acetic Acid SCHEMBL2170653 0.97 FOLH1 (0.39) FOLH1ITGB3ITGA2BALOX15C3AR1
Acetic Acid SCHEMBL160844 0.97 FOLH1 (0.39) FOLH1ITGB3ITGA2BALOX15C3AR1
Acetic Acid SCHEMBL1551710 0.97 FOLH1 (0.39) FOLH1ITGB3ITGA2BALOX15C3AR1
SCHEMBL8663352 0.95 FOLH1 (0.43) FOLH1ALOX15MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1612 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001910-A1 PEPTIDES AND USES THEREOF PREVECEUTICAL MEDICAL INC (CA) 2026-01-01 — — US claimed
US-20250325672-A1 ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS BICYCLE TX LTD (GB) 2025-10-23 — — US claimed
US-20240391954-A1 MC4R AGONIST PEPTIDES THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2024-11-28 — — US claimed
EP-4433495-A1 PEPTIDES AND USES THEREOF Preveceutical Medical Inc. (CA) 2024-09-25 — — EP claimed
US-20240301023-A1 PEPTIDES AND USES THEREOF PreveCeutical Medical Inc. (CA) 2024-09-12 — — US claimed
EP-4392072-A1 MC4R AGONIST PEPTIDES The Regents Of The University Of Michigan (US) 2024-07-03 — — EP claimed
US-20240108737-A1 ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS UNITED KINGDOM RESEARCH AND INNOVATION (GB) 2024-04-04 — — US claimed
CN-117083287-A Antiinfective bicyclic peptide ligands 拜斯科技术开发有限公司 2023-11-17 — — CN claimed
EP-4274839-A1 ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS BicycleTx Limited (GB) 2023-11-15 — — EP claimed
EP-4274840-A1 ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS BicycleTx Limited (GB) 2023-11-15 — — EP claimed
US-20130130263-A1 GAMETES SEPARATION METHODS, COMPOSITIONS AND USES THEREOF ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) 2013-05-23 — — US claimed
EP-2539434-A1 GAMETES SEPARATION METHODS, COMPOSITIONS AND USES THEREOF Assistance Publique - Hôpitaux de Paris (FR) 2013-01-02 — — EP claimed
WO-2011104336-A1 GAMETES SEPARATION METHODS, COMPOSITIONS AND USES THEREOF ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (FR) 2011-09-01 — — WO claimed
EP-2361967-A1 Gametes separation methods, compositions and uses thereof Assistance Publique - Hôpitaux de Paris (FR) 2011-08-31 — — EP claimed
US-20090298747-A1 Methods and Compositions For Treatment of Nitric Oxide-Induced Clinical Conditions BIO HOLDING, INC. (US) 2009-12-03 — — US claimed
US-20090215895-A1 Therapeutic and carrier molecules PEPLIN BIOLIPIDS PTY LTD (AU) 2009-08-27 — — US claimed
US-7256172-B1 Method of treatment and agents useful for same THE UNIVERSITY OF MELBOURNE (AU) 2007-08-14 — — US claimed
US-20040220113-A1 Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions BIO HOLDING, INC. 2004-11-04 — — US claimed
US-20040220242-A1 Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions BIO HOLDING, INC. 2004-11-04 — — US claimed
EP-0850950-A1 PEPTIDE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1998-07-01 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215895-A1 Therapeutic and carrier molecules PHKG1, PHKG2, DGKB FOLH1 2178/4885ITGB3 3284/4885ITGA2B 3053/4885
US-20240301023-A1 PEPTIDES AND USES THEREOF OPRL1, OPRK1, OPRM1 FOLH1 573/4885ITGB3 3775/4885ITGA2B 3894/4885
US-20250325672-A1 ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS ACE2, SARS1, TMPRSS2 FOLH1 798/4885ITGB3 1721/4885ITGA2B 3350/4885
US-20240391954-A1 MC4R AGONIST PEPTIDES MC4R, MC3R, MC5R FOLH1 2807/4885ITGB3 3607/4885ITGA2B 4492/4885
US-20240108737-A1 ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS ACE2, SARS1, TMPRSS2 FOLH1 952/4885ITGB3 1004/4885ITGA2B 2748/4885
US-20260001910-A1 PEPTIDES AND USES THEREOF MMP3, PEPD, MMP9 FOLH1 88/4885ITGB3 1350/4885ITGA2B 2285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.